Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MRVI vs ARVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARVN Captures Overall Composite Edge (52.9 HOLD vs 49.0 HOLD), While MRVI Leads 4–2 on Growth & Valuation Pillars

ARVN Overall Winner 6-Pillar Tally: MRVI 4 – 2 ARVN Matrix Metrics: MRVI 3 – 7 ARVN

As of Nov 16, 2026, Arvinas, Inc (ARVN) captures the overall head-to-head institutional edge over Maravai LifeSciences Holdings, Inc. (MRVI) on higher Unified Composite conviction (52.9/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while MRVI wins 4–2 across the 6-pillar growth and valuation breakdown. MRVI trades at $7.45 (N/M Forward P/E, -24.2% operating margin) versus ARVN at $6.74 (17.9x Forward P/E, -10.1% operating margin).

  • Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. MRVI 49.0/100 HOLD) and 1.40β · 66% Vol risk profile, whereas MRVI leads top-line expansion (+10.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MRVI trades in a Neutral technical trend (BREAKOUT options phase, RSI 49.1); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRVI vs ARVN
MRVI NASDAQ
Maravai LifeSciences Holdings, Inc. Class A Common Stock
Pharmaceutical Preparations
$7.45
-1.19% 1D
Market Cap $2.0B
TTM Revenue $213M
Forward P/E N/M
Beta / 30D Vol 1.61β · 83% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 37.0 Fund 48.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $7.64 · SMA50: $7.40
ARVN NASDAQ Head-to-Head Winner
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57

6-Pillar Scorecard Institutional Category Breakdown (MRVI 4 – 2 ARVN)

Columns: Metric · MRVI · ARVN
1. Valuation Multiples ARVN
Forward P/E N/M 17.9x
Trailing P/E N/M 17.9x
PEG Ratio N/M N/M
EV / Revenue 9.9x 1.3x
2. Growth & Scale MRVI
Revenue Growth (YoY) +10.1% -98.8%
Earnings Growth (YoY) -32.7% +0.0%
TTM Revenue (USD) $213M $275M
Market Cap $2.0B $449.9M
3. Profitability & Quality ARVN
Gross Margin 39.9% 96.7%
Operating Margin -24.2% -10.1%
Net Profit Margin -30.8% -3.5%
Return on Equity (ROE) -29.8% -1.8%
4. Balance Sheet & Cash Flow MRVI
Cash Generation (TTM) -$13M -$160M
Cash Flow Margin -5.9% -58.0%
Net Cash / Leverage $103M Net Debt (0.90x D/E) $81M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRVI
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 111.8% (17th %ile) 108.7% (25th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MRVI
OpEx & R&D Intensity 64.1% of Rev ($137M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRVI (3) vs ARVN (7)
Institutional Metric MRVI ARVN Criterion Row Edge
Market Capitalization
Scale
$2.0B $449.9M Larger Scale MRVI
Trailing P/E Ratio
Valuation
N/M 17.9x Lower Multiple ARVN
Forward P/E Ratio
Valuation
N/M 17.9x Lower Multiple ARVN
Revenue Growth (YoY)
Growth
+10.1% -98.8% Higher Growth MRVI
Operating Margin (TTM)
Profitability
-24.2% -10.1% Higher Margin ARVN
Net Profit Margin
Profitability
-30.8% -3.5% Higher Margin ARVN
Return on Equity (ROE)
Capital Efficiency
-29.8% -1.8% Higher ROE ARVN
52-Week Range Position
Momentum
70% ($3–$9) 5% ($6–$15) Stronger Trend MRVI
Beta / 30D Volatility
Risk Regime
1.61β · 83% Vol 1.40β · 66% Vol Lower Realized Risk ARVN
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 52.9 / 100 (HOLD) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
$213M $275M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
39.9% 96.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.9x EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$13M ($103M Net Debt (0.90x D/E)) -$160M ($81M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRVI +13.02 pp
MRVI: +9.72% · ARVN: -3.3%
3M Horizon MRVI +57.0 pp
MRVI: +29.79% · ARVN: -27.21%
6M Horizon MRVI +105.83 pp
MRVI: +82.6% · ARVN: -23.23%
1Y Horizon MRVI +162.63 pp
MRVI: +129.23% · ARVN: -33.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRVI Revenue ARVN Revenue MRVI Op. Margin ARVN Op. Margin Margin Leader
FY2018 N/A $10M N/A -306.3% ARVN
FY2019 $140M $20M 16.8% -281.4% MRVI
FY2020 $280M $20M 42.2% -554.1% MRVI
FY2021 $800M $50M 69.4% -403.4% MRVI
FY2022 $880M $130M 65.0% -200.3% MRVI
FY2023 $290M $80M -11.0% -511.5% MRVI
FY2024 $260M $260M -90.9% -95.0% MRVI
FY2025 $190M $260M -115.9% -45.1% ARVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRVI BREAKOUT
98d in phase · OBV DISTRIBUTION
Current IV 111.8%
IV Percentile 17th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MRVI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRVI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.0B market capitalization and -24.2% operating margin.
OpEx & R&D Reinvestment 64.1% of Rev ($137M)
90D Engineering Disclosures 0 Published
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MRVI vs ARVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Arvinas, Inc (ARVN) captures the overall head-to-head institutional edge over Maravai LifeSciences Holdings, Inc. (MRVI) on higher Unified Composite conviction (52.9/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while MRVI wins 4–2 across the 6-pillar growth and valuation breakdown. MRVI trades at $7.45 (N/M Forward P/E, -24.2% operating margin) versus ARVN at $6.74 (17.9x Forward P/E, -10.1% operating margin). Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. MRVI 49.0/100 HOLD) and 1.40β · 66% Vol risk profile, whereas MRVI leads top-line expansion (+10.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MRVI trades in a Neutral technical trend (BREAKOUT options phase, RSI 49.1); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRVI leads the Growth & Scale pillar: MRVI posts +10.1% YoY revenue growth and -32.7% YoY earnings growth on $213M TTM revenue (39.9% gross margin, -24.2% operating margin), compared with ARVN at -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRVI cumulative revenue shifted +35.7% while ARVN shifted +2500.0%. In operating R&D and SG&A reinvestment, MRVI deploys 64.1% of Rev ($137M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARVN.

ARVN screens cheaper on headline valuation multiples. MRVI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.9x EV/Revenue (-5.9% FCF margin), whereas ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRVI (-29.8% ROE) versus ARVN (-1.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MRVI carries 111.8% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.61β · 83% Vol realized risk). By comparison, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.